A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Conditions

• AML (Acute Myelogenous Leukemia)
• Acute Lymphoid Leukemia (ALL)
• Acute Leukemia (Category)
• MDS (Myelodysplastic Syndrome)
• CML (Chronic Myelogenous Leukemia)
• CLL (Chronic Lymphocytic Leukemia)
• Prolymphocyctic Leukemia
• Chronic Myelomonocytic Leukemia (CMML)
• Myeloproliferative Neoplasm (MPN)
• Lymphoma
• Myelofibrosis

Interventions

• DRUG: Conditioning Regimen A
• DRUG: Conditioning Regimen B
• DRUG: Conditioning Regimen C
• DRUG: Conditioning Regimen D
• DRUG: Conditioning Regimen E
• PROCEDURE: Hematopoietic Cell Transplantation
• DRUG: PTCy (50 mg/kg D3, D4)
• DRUG: PTCy (25 mg/kg D3, D4)
• DRUG: Post-transplant Tacrolimus
• DRUG: Post-transplant Mycophenolate mofetil
• DRUG: Post-transplant Abatacept
• DRUG: Post-transplant Ruxolitinib
• DRUG: Supportive Care: Growth Factors
• PROCEDURE: Supportive Care: Blood Products
• OTHER: Supportive Care: Infection Prophylaxis
• OTHER: Supportive Care: Intravenous immune globulin (IVIG)
• DRUG: Supportive Care: Seizure prophylaxis
• OTHER: Supportive Care: Monitoring and management of CRS
• OTHER: Supportive Care: Prophylaxis against infections
• DRUG: Supportive Care: Prophylaxis against infections

Sponsor

Center for International Blood and Marrow Transplant Research

Collaborators

• [object Object]
• [object Object]